Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

Rhea-AI Summary

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced its participation at the Jefferies Healthcare Conference in New York, scheduled for June 9, 2022. The management team will hold a fireside chat at 10:30 a.m. ET and will be available for one-on-one meetings on June 8 and 9. The company focuses on innovative eye disease therapies, utilizing its AMPPLIFY® drug delivery technology. Notably, on May 23, 2022, Kala agreed to sell its commercial portfolio to Alcon Inc., with the transaction expected to close in Q3 2022, pending regulatory conditions.

ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference in New York, NY. Members from the management team are scheduled to participate in a fireside chat on Thursday, June 9, 2022 at 10:30 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 8, 2022 and Thursday, June 9, 2022.

To access the webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY^® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS^® (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS^® (loteprednol etabonate ophthalmic suspension) 1%. On May 23, 2022, the Company announced that it entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. The Company anticipates the transaction will close in the third quarter of 2022, subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The Company also has a pipeline of development programs including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple proprietary new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:

Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

FAQ

When will Kala Pharmaceuticals present at the Jefferies Healthcare Conference?

Kala Pharmaceuticals will present on June 9, 2022, at 10:30 a.m. ET.

What is the focus of Kala Pharmaceuticals?

Kala Pharmaceuticals specializes in therapies for diseases of the eye.

What significant agreement did Kala Pharmaceuticals announce on May 23, 2022?

Kala Pharmaceuticals entered a definitive agreement to sell its commercial portfolio to Alcon Inc.

When is the expected closing date for Kala's transaction with Alcon Inc.?

The transaction is expected to close in the third quarter of 2022.

What technology does Kala Pharmaceuticals use for drug delivery?

Kala utilizes AMPPLIFY® mucus-penetrating particle technology for its ocular therapies.